Artisan Partners Limited Partnership Purchases Shares of 49,065 Guardant Health, Inc. (NASDAQ:GH)

Artisan Partners Limited Partnership acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 49,065 shares of the company's stock, valued at approximately $1,499,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Guardant Health in the 4th quarter worth $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health during the fourth quarter worth about $43,000. Kimelman & Baird LLC acquired a new position in shares of Guardant Health during the 4th quarter worth about $58,000. Quantbot Technologies LP bought a new stake in shares of Guardant Health in the 4th quarter valued at about $80,000. Finally, Jones Financial Companies Lllp raised its position in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after acquiring an additional 817 shares during the period. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on GH. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Morgan Stanley upped their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Scotiabank lifted their target price on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Canaccord Genuity Group increased their price target on Guardant Health from $42.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, February 24th. Finally, Stephens reaffirmed an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $48.95.

Remove Ads

Guardant Health Stock Performance

GH traded down $2.06 on Thursday, hitting $41.43. 368,031 shares of the company were exchanged, compared to its average volume of 2,135,204. The stock's fifty day moving average is $44.65 and its 200-day moving average is $34.66. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89. The company has a market cap of $5.11 billion, a PE ratio of -11.64 and a beta of 1.50.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.